Wikipedia

Kahn Sagol Maccabi

The Kahn-Sagol-Maccabi (KSM) for Research and Innovation (in Hebrew: מכון קאהן-סגול-מכבי למחקר ולחדשנות) is the Research and Innovation Center of Maccabi Healthcare Services.[1]

The Kahn-Sagol-Maccabi for Research and Innovation
מכון קאהן-סגול-מכבי למחקר ולחדשנות (Hebrew)
TypeMedical research
Established2016
Location
Israel
Websitewww.ksminnovation.com

History

edit

Founded in 2016 by Maccabi Health Services with the key support of Morris Kahn and Sami Sagaol, KSM promotes excellence in medical research.[2]

It wasa formerly headed by Prof. Varda Shalev and is currently headed by Dr. Tal Patalon.[3]

Activities and services

edit

Medical studies

edit

KSM Center strives to enhance healthcare systems through independent research and partnerships with international researchers,[4] academic institutions, pharmaceutical companies, start-ups and technology firms.[5][6]

Since its inception, the center has conducted hundreds of studies,[7] resulting in the development of tools for both patients and healthcare providers.[8] These studies have influenced medical policies in several countries, particularly during the COVID-19 pandemic.[9]

Notable studies conducted under KSM's auspices include:

  • Studies on the coronavirus epidemic – During the COVID-19 pandemic, several international scientific studies based on the Maccabi databases were conducted by the center, Including studies on repeated infection in children,[10] repeated infection in adults,[11] natural vaccination,[12][9][13] reduction of transmission[14] the decline in the effect of the third vaccine[15] the effect of the vaccine on intra-domestic infection[16] and on patients with Coeliac disease.[17]
  • Research on mpox – In 2023, a study on mpox based on KSM's analysis and database was published.[18]
  • Research on Parvovirus B19 – In 2023, a study on a local outbreak of parvovirus was published.[19]
  • Research on autism – In 2023, a study on late diagnosis of autism was published.[20]
  • Research on cancer – In 2023, a study of the effects of palbociclib treatment on the lifespan of patients with breast cancer was published.[21]

Medical database

edit

KSM's research activities are based on independent efforts, as well as the extensive medical knowledge and database of Maccabi Health Services.[22] This database, compiled over three decades and anonymized, encompasses digital records of 2.7 million insured individuals.[23]

In addition to its in-house research,[24] the Center offers global researchers access to conduct studies, analyses [30] and medical prediction,[25] based on this comprehensive database.[26]

KSM's innovation and big data department leverages databases and artificial intelligence technologies,[27][28] facilitating a wide range of research opportunities, analysis and medical prediction.[29]

Biobank

edit

The KSM Center has established the Tipa BioBank,[30] Israel's largest biobank[31] housing over a million genetic samples for research purposes.[32][8]

The purpose of this initiative is to develop tools for early disease detection through genetic[33] and biological studies.[34] A central feature of this effort is the creation of a repository of biological samples (e.g., blood, urine, etc.), enabling researchers to investigate how genetic profiles influence disease risk and treatment.[35]

Main publications

edit

References

edit
  1. ^ The Kahn-Sagol-Maccabi (KSM) Institute for Research and Innovation
  2. ^ "Kahn Sagol Maccabi". Guidestar. Retrieved 9 November 2023.
  3. ^ Big data unit Kahn-Sagol-Maccabi (KSM)
  4. ^ Neesha Salian, SEHA and Israel’s leading HMO announce collaboration in research and digital health development, Gulf Business, 13 July 2022
  5. ^ Maccabi’s KSM Research and Innovation Center Announces Partnership with Rhino Health to Facilitate Healthcare Data Collaborations, Accesswire 25 October 2022
  6. ^ PrognomiQ, Maccabi Health Collaborating on Cancer Biomarker Development, 360dx.com, 21 June 2022
  7. ^ Professional publications, KSM Research and Innovation Center
  8. ^ a b Rubinstein, Carrie (9 September 2022). "Small-Big Data: A Healthcare Revolution In The Making". Forbes. Retrieved 26 October 2023.
  9. ^ a b Patalon, Tal; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Gazit, Sivan (2023). "Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents". The Journal of Pediatrics. 257. doi:10.1016/j.jpeds.2023.02.016. PMC 9981270. PMID 36870558.
  10. ^ Gazit, Sivan; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Stuart, Elizabeth A.; Patalon, Tal (2023). "Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: A target trial emulation". The Lancet Microbe. 4 (7): e495–e505. doi:10.1016/S2666-5247(23)00103-9. PMC 10101759. PMID 37062294.
  11. ^ Gazit, S.; Shlezinger, R.; Perez, G.; Lotan, R.; Peretz, A.; Ben-Tov, A.; Herzel, E.; Alapi, H.; Cohen, D.; Muhsen, K.; Chodick, G.; Patalon, T. (2022). "The Incidence of SARS-CoV-2 Reinfection in Persons with Naturally Acquired Immunity with and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine: A Retrospective Cohort Study". Annals of Internal Medicine. 175 (5): 674–681. doi:10.7326/M21-4130. PMC 8855786. PMID 35157493.
  12. ^ Patalon, Tal; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Gazit, Sivan (2023). "Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents". The Journal of Pediatrics. 257. doi:10.1016/j.jpeds.2023.02.016. PMC 9981270. PMID 36870558.
  13. ^ Patalon, Tal; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Gazit, Sivan (2023). "Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents". The Journal of Pediatrics. 257. doi:10.1016/j.jpeds.2023.02.016. PMC 9981270. PMID 36870558.
  14. ^ van Boven, Michiel; van Dorp, Christiaan H.; Westerhof, Ilse; et al. (29 January 2024). "Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study". PLOS Computational Biology. 20 (1): e1011832. doi:10.1371/journal.pcbi.1011832. ISSN 1553-7358. medRxiv 10.1101/2023.06.02.23290879. PMC 10852262. PMID 38285727.
  15. ^ Patalon, Tal; Saciuk, Yaki; Peretz, Asaf; Perez, Galit; Lurie, Yoav; Maor, Yasmin; Gazit, Sivan (2022). "Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine". Nature Communications. 13 (1): 3203. Bibcode:2022NatCo..13.3203P. doi:10.1038/s41467-022-30884-6. PMC 9184525. PMID 35680872.
  16. ^ Prunas, Ottavia; Warren, Joshua L.; Crawford, Forrest W.; Gazit, Sivan; Patalon, Tal; Weinberger, Daniel M.; Pitzer, Virginia E. (2022). "Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel". Science. 375 (6585): 1151–1154. Bibcode:2022Sci...375.1151P. doi:10.1126/science.abl4292. PMC 9261115. PMID 35084937.
  17. ^ Ben-Tov, Amir; Lebwohl, Benjamin; Banon, Tamar; Chodick, Gabriel; Kariv, Revital; Assa, Amit; Gazit, Sivan; Patalon, Tal (2023). "BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign". Viruses. 15 (9): 1968. doi:10.3390/v15091968. PMC 10534420. PMID 37766374.
  18. ^ Patalon, Tal; Perez, Galit; Saciuk, Yaki; Refaeli, Ziva; Gazit, Sivan (2023). "Mpox Patient Journey in Israel". Microorganisms. 11 (4): 1042. doi:10.3390/microorganisms11041042. PMC 10145053. PMID 37110465.
  19. ^ Patalon, Tal; Saciuk, Yaki; Trotzky, Daniel; Pachys, Gal; Ben-Tov, Amir; Segal, Yaakov; Gazit, Sivan (2023). "An Outbreak of Parvovirus B19 in Israel". Viruses. 15 (11): 2261. doi:10.3390/v15112261. PMC 10674631. PMID 38005937.
  20. ^ Davidovitch, Michael; Gazit, Sivan; Patalon, Tal; Leitner, Yael; Rotem, Ran S. (2023). "Late diagnosis of autism spectrum disorder—Journey, parents' concerns, and sex influences". Autism Research. 16 (2): 294–301. doi:10.1002/aur.2869. PMID 36495248. S2CID 254561408.
  21. ^ Moser, Sarah Sharman; Mazursky, Orr Friedman; Shalev, Hadas; Apter, Lior; Chodick, Gabriel; Siegelmann-Danieli, Nava (2023). "Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations". Future Oncology. 19 (21): 1473–1483. doi:10.2217/fon-2023-0176. PMID 37529919.
  22. ^ Valo Health, KSM research and innovation center and Valo health announce first of its kind multiyear collaboration to spearhead preventive care and personalized medicine for patients, 19 Sep 2022
  23. ^ Kraus, Yair (1 August 2023). ""Artificial intelligence is going to lead to a change the likes of which we haven't seen in years in the world of medicine"". Ynet. Retrieved 9 November 2023.
  24. ^ Yanko, Adir (25 March 2021). "A significant increase in the diagnosis of young celiac patients in Israel – what are the reasons for this?". Ynet. Retrieved 26 October 2023.
  25. ^ Yechezkel, Matan; Mofaz, Merav; Painsky, Amichai; Patalon, Tal; Gazit, Sivan; Shmueli, Erez; Yamin, Dan (2023). "Safety of the fourth COVID-19 BNT162b2 mRNA (Second booster) vaccine: A prospective and retrospective cohort study". The Lancet Respiratory Medicine. 11 (2): 139–150. doi:10.1016/S2213-2600(22)00407-6. PMC 9889528. PMID 36410364.
  26. ^ Weinerb, Gali (1 December 2020). "Predicting illnesses and hospitalizations: the vision of the director of the Maccabi Research Institute". Globes. Retrieved 26 October 2023.
  27. ^ Danny Sullivan, Longevity AI partners with Israel’s leading HMO, Technology, 4 April 2023
  28. ^ IBEX Introduces Galen Gastric, World’s First AI-Powered Solution For Gastrointestinal Cancer Diagnostics, At Maccabi Healthcare Services, AIthority.com, 24 August 2021
  29. ^ Suresh, Somasetty (25 October 2023). "New Study Shows Pfizer COVID-19 Vaccine Equally Effective for Patients with Celiac Disease". Express Healthcare Management. Retrieved 26 October 2023.
  30. ^ The Tipa Biobank, Kahn-Sagol-Maccabi (KSM)
  31. ^ KSM Research And Innovation And Genetika+ Partner To Seek AI Solutions For Personalization Of Depression Treatment, 15 August 2022
  32. ^ "Abu Dhabi DoH and Kahn Sagol Maccabi (KSM) Sign an MoU to Cooperate in Technological Innovation and Healthcare Research". AP news. 1 February 2023. Retrieved 26 October 2023.
  33. ^ G42 Healthcare, KSM enter first UAE-Israel genetic research collaboration – Arabian Business, Arabian Business, 2 March 2022
  34. ^ Rubinstein, Carrie (12 July 2023). "Apparently Getting Smarter Makes Us Healthier: AI And Data Analysis Revolutionize Healthcare". Forbes. Retrieved 26 October 2023.
  35. ^ Israel and UAE to collaborate on cancer and diabetes research, MiddleEastMonitor ,14 July 2022
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kahn_Sagol_Maccabi&oldid=1253047091"